TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16315875

Group type: EXPERIMENTAL
Intervention: Cimetidine administration during chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-administration of cimetidine during chemotherapy
Number of subjects: 0
Study: 11782685

Group type: EXPERIMENTAL
Intervention: Cefaclor AF (500 mg BID for 10 days)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Cefuroxime axetil (250 mg BID for 10 days)
Number of subjects: 170
Study: 9440719

Group type: EXPERIMENTAL
Intervention: VMP (etoposide, mitoxantrone, and prednimustine)
Number of subjects: 130

Group type: COMPARATOR
Intervention: CHOP (cyclophosphamide, doxorobucin, vincristine, and prednisone)
Number of subjects: 130
Study: 7912567

Group type: EXPERIMENTAL
Intervention: EGFR positive tumors
Number of subjects: 241

Group type: COMPARATOR
Intervention: EGFR negative tumors
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: EGFR and c-erbB-2 protein expressing group
Number of subjects: 241
Study: 2563327

Group type: EXPERIMENTAL
Intervention: Home-based treatment with massed exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based treatment with spaced exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based treatment with self-controlled exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based treatment with therapist-controlled exposure
Number of subjects: 0
Study: 31833974

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-HER2 therapy
Number of subjects: 0
Study: 31134724

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan initiated ≥ 12-h pre-discharge
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Sacubitril/valsartan initiated between Days 1–14 post-discharge
Number of subjects: 1002
Study: 28520886

Group type: EXPERIMENTAL
Intervention: Barrier device covering the anaesthesia workstation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no barrier device)
Number of subjects: 42
Study: 27682868

Group type: EXPERIMENTAL
Intervention: Financial incentives (£15 for each LAI medication)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 141
Study: 24930179

Group type: EXPERIMENTAL
Intervention: Training involving throwing with visual feedback during training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Training involving throwing without visual feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training involving throwing with visual feedback
Number of subjects: 0
Study: 23098408

Group type: EXPERIMENTAL
Intervention: Training program for NPCs in advanced neonatal and obstetric care
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 50
Study: 20129316

Group type: EXPERIMENTAL
Intervention: Souvenaid (medical food)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 225
Study: 17321159

Group type: EXPERIMENTAL
Intervention: ISB‐IV
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: ISB‐IL
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: IL
Number of subjects: 84

Group type: COMPARATOR
Intervention: IV
Number of subjects: 84
Study: 16277295

Group type: EXPERIMENTAL
Intervention: Simultaneous presentation of drifting gratings (spatially separated)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interstimulus interval of at least 1000 ms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two reference speeds tested: 2 deg/s and 8 deg/s
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Staircase method of estimating thresholds
Number of subjects: 0
Study: 12166571

Group type: EXPERIMENTAL
Intervention: Enhanced follow‐up (EF)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Conventional follow‐up (CF)
Number of subjects: 109
Study: 9607059

Group type: EXPERIMENTAL
Intervention: Live human rotavirus vaccine 89-12 (10^5 p.f.u. dose-1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 11835845

Group type: EXPERIMENTAL
Intervention: Local homoharringtonine and dexamethasone treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Local dexamethasone treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: No drug treatment (untreated group)
Number of subjects: 54
Study: 15278645

Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine solution (pH 7.12)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Commercial 1.5% lidocaine with epinephrine (pH 5.72)
Number of subjects: 34
Study: 6870483

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentobarbital
Number of subjects: 0
Study: 31361909

Group type: EXPERIMENTAL
Intervention: Trypsin plus collagenase
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Trypsin alone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Dermabrasion with vehicle alone
Number of subjects: 22
Study: 30770525

Group type: EXPERIMENTAL
Intervention: Prototype Willingness Model (PWM) based interventions
Number of subjects: 315
Study: 28593698

Group type: EXPERIMENTAL
Intervention: Receptive language
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Expressive language
Number of subjects: 200
Study: 26481726

Group type: EXPERIMENTAL
Intervention: Subthreshold HD stimulation (1200 Hz/200 μsec/amplitude 90% paresthesia threshold)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Conventional stimulation (60 Hz/350 μsec)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study: 26600007

Group type: EXPERIMENTAL
Intervention: 200mg of mifepristone per day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 65
Study: 23905371

Group type: EXPERIMENTAL
Intervention: Bushen huoxue recipe (BHR)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Conjugated estrogens and medroxyprogesterone acetate
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: BHR + conjugated estrogens and medroxyprogesterone acetate
Number of subjects: 265
Study: 21459975

Group type: EXPERIMENTAL
Intervention: Group therapy intervention (manual based developmental group therapy programme)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 366
Study: 19828574

Group type: EXPERIMENTAL
Intervention: Simulated patient (SP) visits with feedback
Number of subjects: 56

Group type: COMPARATOR
Intervention: Pharmacy educators (PE) feedback
Number of subjects: 56
Study: 16888872

Group type: EXPERIMENTAL
Intervention: Lung-volume-reduction surgery (LVRS)
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Lung-volume-reduction surgery (LVRS) in upper-lobe patients with low exercise capacity
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Lung-volume-reduction surgery (LVRS) in upper-lobe-predominant and high-exercise-capacity patients
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 1218
Study: 15639688

Group type: EXPERIMENTAL
Intervention: EZE/SIMVA (10/10, 10/20, 10/40, or 10/80 mg)
Number of subjects: 1528

Group type: EXPERIMENTAL
Intervention: EZE/SIMVA
Number of subjects: 1528

Group type: COMPARATOR
Intervention: SIMVA
Number of subjects: 1528
Study: 11730077

Group type: EXPERIMENTAL
Intervention: Affective psychotic patients
Number of subjects: 707

Group type: COMPARATOR
Intervention: Schizophrenic patients
Number of subjects: 707
Study: 10667618

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/day, increased to 100 mg/day if necessary)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Moclobemide (300 mg/day, increased to 450 mg/day if necessary)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 197

Group type: COMPARATOR
Intervention: Moclobemide
Number of subjects: 197
Study: 7701456

Group type: EXPERIMENTAL
Intervention: Autogenic drainage
Number of subjects: 18

Group type: COMPARATOR
Intervention: Active cycle of breathing techniques (ACBT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: ACBT
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 18
Study: 2926343

Group type: EXPERIMENTAL
Intervention: American Lung Association's Because You Love Your Baby smoking intervention (ALA)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard-of-care protocol (non-ALA)
Number of subjects: 109
Study: 343748

Group type: EXPERIMENTAL
Intervention: Intraluminal fluorouracil (30 mg/kg) with intravenous fluorouracil (10 mg/kg) on the first two postoperative days and five subsequent courses of oral fluorouracil (90 mg/kg) over one year.
Number of subjects: 203

Group type: COMPARATOR
Intervention: Intraluminal control (saline)
Number of subjects: 203
Study: 31264294

Group type: EXPERIMENTAL
Intervention: High-dose CBD co-administered with THC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (implied control)
Number of subjects: 0
Study: 30450532

Group type: EXPERIMENTAL
Intervention: Chemotherapy (paclitaxel/carboplatin with or without bevacizumab)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Leptin/adiponectin ratio (L/A) before treatment
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Adiponectin and leptin levels
Number of subjects: 43
Study: 27809651

Group type: EXPERIMENTAL
Intervention: NiTiBOND® prosthesis (nitinol group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fully fluoroplastic piston (fluoroplastic group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fully titanium piston (first titanium group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fully titanium piston (last titanium group)
Number of subjects: 50
Study: 25633893

Group type: EXPERIMENTAL
Intervention: Polynephron dialysis membrane
Number of subjects: 47

Group type: COMPARATOR
Intervention: Helixone and polyamide (control)
Number of subjects: 47
Study: 23807065

Group type: EXPERIMENTAL
Intervention: Female Veterans reporting sexual harassment
Number of subjects: 2344

Group type: EXPERIMENTAL
Intervention: Female Veterans reporting combat exposure
Number of subjects: 2344

Group type: COMPARATOR
Intervention: Probable PTSD symptoms in female and male Veterans
Number of subjects: 2344

Group type: COMPARATOR
Intervention: Symptomatic anxiety in female and male Veterans
Number of subjects: 2344

Group type: EXPERIMENTAL
Intervention: Probable depression in female Veterans
Number of subjects: 2344

Group type: EXPERIMENTAL
Intervention: Problematic alcohol use in female Veterans
Number of subjects: 2344

Group type: EXPERIMENTAL
Intervention: Harassment stress and PTSD in female Veterans
Number of subjects: 2344

Group type: COMPARATOR
Intervention: Harassment stress and PTSD in male Veterans
Number of subjects: 2344

Group type: EXPERIMENTAL
Intervention: Combat stress and PTSD in female Veterans
Number of subjects: 2344

Group type: COMPARATOR
Intervention: Combat stress and PTSD in male Veterans
Number of subjects: 2344
Study: 21688658

Group type: EXPERIMENTAL
Intervention: Multimodal analgesia with paracetamol, lornoxicam, and epidural ropivacaine (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multimodal analgesia with paracetamol, epidural ropivacaine, and tramadol (Group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Monoanalgesia with promedol (Comparison Group)
Number of subjects: 30
Study: 19054793

Group type: EXPERIMENTAL
Intervention: Brachial artery flow‐mediated dilation (BAFMD) in healthy individuals (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Brachial artery flow‐mediated dilation (BAFMD) in pooled patients (Group B + C)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparison between groups B and C
Number of subjects: 80

Group type: COMPARATOR
Intervention: Correlation of ankle‐brachial index/BAFMD
Number of subjects: 80
Study: 16430565

Group type: EXPERIMENTAL
Intervention: Gel lubrication
Number of subjects: 55

Group type: COMPARATOR
Intervention: No gel lubrication (control)
Number of subjects: 55
Study: 15272096

Group type: EXPERIMENTAL
Intervention: Mild or moderate to severe level of depressive symptoms at hospitalization
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Self-reported previous diagnosis of a cardiac condition
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Self-reported history of depression, anxiety, or stress
Number of subjects: 833
Study: 11378806

Group type: EXPERIMENTAL
Intervention: High phenol diet (69 g per day of extra virgin olive oil rich in phenols)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Low phenol diet (69 g per day of extra virgin olive oil poor in phenols)
Number of subjects: 46
Study: 9463202

Group type: EXPERIMENTAL
Intervention: 30 mg of ketorolac
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (1 ml of 0.9% saline solution)
Number of subjects: 26
Study: 10442378

Group type: EXPERIMENTAL
Intervention: Gemcitabine and UFT plus oral calcium folinate
Number of subjects: 8
Study: 2198315

Group type: EXPERIMENTAL
Intervention: 800 mg pefloxacin (PEFLO) once daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 400 mg ofloxacin (OFLO) once daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combined therapy with WHO/MDT regimen
Number of subjects: 21
Study: 412079

Group type: EXPERIMENTAL
Intervention: Cetal retard
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cinnarizine
Number of subjects: 54
Study: 31396794

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Laser acupuncture therapy (LAT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (sham laser)
Number of subjects: 45
Study: 31567928

Group type: EXPERIMENTAL
Intervention: Laparoscopic total mesorectal excision
Number of subjects: 71
Study: 28614895

Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy
Number of subjects: 534

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 534
Study: 26066346

Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV) powder boosted with ritonavir (RTV) liquid plus optimized dual nucleoside reverse-transcriptase inhibitor (NRTI) background therapy
Number of subjects: 56
Study: 23296830

Group type: COMPARATOR
Intervention: Limit-fed creep feed with no trace mineral supplementation (Nonsup)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Limit-fed creep feed with trace mineral fortification (MIN+)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Limit-fed creep feed without trace mineral fortification (MIN-)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Limit-fed creep feed (LFC)
Number of subjects: 34
Study: 21875474

Group type: EXPERIMENTAL
Intervention: Yanshu injection combined with IMRT and concomitant chemotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (IMRT and concurrent chemotherapy)
Number of subjects: 60
Study: 19335225

Group type: EXPERIMENTAL
Intervention: Wearing gloves for 90 minutes or less
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Wearing gloves for 91-150 minutes
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Wearing gloves for more than 150 minutes
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Surgeons
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: First assistants
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Surgical nurses
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Use of hand cream (cornstarch and ethanol)
Number of subjects: 898
Study: 16449273

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cardiopulmonary disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: FEV1 <50% predicted
Number of subjects: 0

Group type: COMPARATOR
Intervention: > or =4 AECBs in previous year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Use of acute bronchodilators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age > or =65 years
Number of subjects: 0
Study: 15038168

Group type: EXPERIMENTAL
Intervention: Glucocorticosteroid administration
Number of subjects: 0
Study: 11156667

Group type: EXPERIMENTAL
Intervention: His bundle ablation (HBA) and VVIR pacemaker
Number of subjects: 36

Group type: COMPARATOR
Intervention: Atrioventricular modifying drugs and VVI pacemaker
Number of subjects: 36
Study: 9414052

Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency neurotomy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 7506182

Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 71

Group type: COMPARATOR
Intervention: Ketoprofen
Number of subjects: 71
Study: 3538487

Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg/day for 14 days)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Serial PEF measurements
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Steroid response
Number of subjects: 33
Study: 29262755

Group type: EXPERIMENTAL
Intervention: Direct contact with mental illness
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Indirect contact with mental illness
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Schizophrenia
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Alcoholism
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Contact experience (direct vs indirect)
Number of subjects: 573
Study: 26796897

Group type: EXPERIMENTAL
Intervention: Active comparator mouthrinse
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Experimental 5% CSPS dentifrice
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Marketed 5% CSPS dentifrices
Number of subjects: 23

Group type: COMPARATOR
Intervention: Negative control dentifrice
Number of subjects: 23
Study: 24959794

Group type: EXPERIMENTAL
Intervention: Relaxation breathing and progressive muscle relaxation (twice a day for 8 weeks)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Wait-list group (no intervention)
Number of subjects: 152
Study: 22428471

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 microg plus hyperbaric bupivacaine 2.5 mg (Group BF)
Number of subjects: 99
Study: 21090162

Group type: EXPERIMENTAL
Intervention: Open ear canal hearing aids with counselling and sound enrichment
Number of subjects: 100
Study: 18523382

Group type: EXPERIMENTAL
Intervention: Mucosa adhesive paste (0.1% F)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mouth rinsing solution (0.2% NaF)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Toothpaste (0.5% F)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Tablet (0.75 mg F)
Number of subjects: 14
Study: 16419491

Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment (Group B)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Untreated subclinical hypothyroidism (Group C)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Normal TSH (Group A)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism (Group B and C)
Number of subjects: 108
Study: 12585791

Group type: EXPERIMENTAL
Intervention: Continuous Passive Motion (CPM) and Standardized Exercises (SEs)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Slider-Board (SB) therapy and Standardized Exercises (SEs)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standardized Exercises (SEs) alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups (CPM, SB therapy, SEs)
Number of subjects: 120
Study: 10539832

Group type: EXPERIMENTAL
Intervention: Platelet glycoprotein IIb/IIIa inhibitor (eptifibatide)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 8762375

Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention programme
Number of subjects: 158
Study: 1817618

Group type: EXPERIMENTAL
Intervention: Thiopentone 0.5 mg kg‐1
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propofol 0.25 mg kg‐1
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 19
Study: 7100824

Group type: EXPERIMENTAL
Intervention: Ornidazole (Tiberal) for 3 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Doxycycline (Vibramycin) for 3 days
Number of subjects: 100
Study: 30991137

Group type: EXPERIMENTAL
Intervention: Curcuma longa (30 mg/kg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28799861

Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy (IAT)
Number of subjects: 397

Group type: COMPARATOR
Intervention: No intra-arterial therapy (COVES = 0)
Number of subjects: 397
Study: 26851974

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 23721506

Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 463
Study: 22664976

Group type: EXPERIMENTAL
Intervention: IDX375 200 mg BID
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: IDX375 (25-200 mg single ascending doses)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 43
Study: 18718110

Group type: EXPERIMENTAL
Intervention: Multidisciplinary pain treatment allocation protocol
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 220
Study: 17578470

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (128 mg slow‐release magnesium stearate)
Number of subjects: 4494

Group type: COMPARATOR
Intervention: Placebo (lactose sugar)
Number of subjects: 4494
Study: 15377574

Group type: EXPERIMENTAL
Intervention: NHS Direct triage
Number of subjects: 4703

Group type: COMPARATOR
Intervention: Practice based triage
Number of subjects: 4703
Study: 11236051

Group type: EXPERIMENTAL
Intervention: Protein hydrolysate formula
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard preterm formula
Number of subjects: 15
Study: 9929229

Group type: EXPERIMENTAL
Intervention: Computerized management of diabetes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no similar intervention)
Number of subjects: 15
Study: 7721525

Group type: EXPERIMENTAL
Intervention: Infant Incubator (INC)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Heated Water-Filled Mattress (HWM)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Space-Heated Room (SHR)
Number of subjects: 62
Study: 2529770

Group type: EXPERIMENTAL
Intervention: Buserelin 1200 micrograms/day for 6 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Danazol 600 micrograms/day for 6 months
Number of subjects: 62
Study: 1097864

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0